Volume One · November 2026By women veterans. For women veterans.
The lifestyle magazine for women veterans
Health & Wellness

FDA adds a rare vision-loss warning to every GLP-1 drug, including Ozempic and Zepbound

The agency found a small increase in a rare optic nerve condition across the class. It did not restrict who can take the drugs.

Before you take a GLP-1, you will want to read this first. The Food and Drug Administration on Monday ordered a labeling change for all approved GLP-1 receptor agonists, the drug class that includes Ozempic and Wegovy (semaglutide), Mounjaro and Zepbound (tirzepatide) and Lilly’s oral Foundayo. The labels will now warn of a potential increased risk of NAION, a rare condition in which the optic nerve swells and can cause sudden vision loss, usually in one eye.

The change goes in the Warnings and Precautions section. It is not a restriction on who can be prescribed the drugs, BioSpace reported. The FDA listed 12 affected products.

What the numbers show

The numbers behind it are small but consistent. The agency reviewed 126 clinical trials with 78,217 patients and identified 15 probable NAION events: 10 among GLP-1 users and five among placebo patients. That works out to about 6.4 events per 100,000 patient-years on a GLP-1, compared with 3.8 for comparison groups. The FDA said NAION cases had been reported for every GLP-1 on the market.

Do not stop a prescribed medication on your own; talk with your prescriber first.

Why the picture is mixed

The real-world picture is mixed. In adults with type 2 diabetes, the FDA’s analysis found no higher risk compared with SGLT-2 inhibitors such as Jardiance, but a higher risk compared with DPP-4 inhibitors such as Januvia. Animal data did not point to a mechanism. The review began after a 2024 study in JAMA Ophthalmology linked semaglutide to NAION.

Context matters here. Many people taking these drugs have diabetes, high blood pressure or sleep apnea, which are themselves NAION risk factors, and the FDA said that overlap makes adverse event reports hard to interpret. Analysts at BMO said they expect little effect on coverage because the condition is rare.

Volume One · November 2026

The free weekly newsletter

The Friday Dismissal

Your week is officially released. Five good reads. One sharp perspective. Zero mandatory fun. Free every Friday, from women veterans who’ve been there.

Keep reading

All stories